[2] Other GLP-1 receptor agonists may be considered, though they share similar mechanisms and potential side effects: Injectable GLP-1 agonists such as dulaglutide (Trulicity), liraglutide (Victoza), or exenatide (Byetta) may be better tolerated by some patients, as they bypass the upper gastrointestinal tract
[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Kagan V.E., Quinn P.J
This inverse relationship is why a low TSH on tirzepatide can indicate levothyroxine overmedication, your body is absorbing more thyroid hormone than intended, so the pituitary reduces TSH production
such patients may require niacin supplementation, which this injection could provide
The European Medicines Agency confirmed NAION as a "very rare" side effect affecting up to 1 in 10,000 patients taking semaglutide for at least one yeara benchmark plaintiffs may use to establish foreseeability
The long-term data on GLP-1 medications is still developing, and for many people, the medication is not intended to be permanent